BenzingaOctober 23, 2026 at 5:17 AM NY4 Days Ago
Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery
Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
